Unique ID issued by UMIN | UMIN000049903 |
---|---|
Receipt number | R000056837 |
Scientific Title | Study on the efficacy and safety of cephalexin for acute uncomplicated cystitis |
Date of disclosure of the study information | 2022/12/26 |
Last modified on | 2023/06/27 12:48:02 |
Study on the efficacy and safety of cephalexin for acute uncomplicated cystitis
Studies on cephalexin for acute uncomplicated cystitis
Study on the efficacy and safety of cephalexin for acute uncomplicated cystitis
Studies on cephalexin for acute uncomplicated cystitis
Japan |
acute uncomplicated cystitis
Urology |
Others
NO
To evaluate the efficacy and safety of cephalexintreatment for acute uncomplicated cystitis.
Safety,Efficacy
Primary efficacy from the end of the medication to 10 days after the end of the medication
Safety
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Cephalexin continuous formulation 500 mg (potency) twice daily for 7 days.
16 | years-old | <= |
Not applicable |
Female
Patients with subjective symptoms of urinary pain, frequency, urinary urgency, and lower abdominal pain. However, patients with no symptoms of cystitis within 4 weeks prior to the current onset.
Pyuria Patients whose pyuria prior to initiation of medication meets any of the following criteria
Urine occult blood test by non-centrifugal urine 10 WBCs/hpf or greater
Urine detector method with non-centrifuged urine positive
Urine sediment sample positive 5 WBCs/hpf or greater
1) Patients who received other antimicrobial agents prior to the start of study drug and whose symptoms are already improving.
2) Patients who have received a cephalosporin antibiotic within 1 week prior to the start of study drug administration
3) Patients with severe infections that are not expected to respond to oral therapy
4) Patients with serious underlying diseases or complications that make it difficult to evaluate the efficacy and safety of the study drug
5) Patients with a history of allergy to cephalosporins
6) Patients with severe cardiac or hepatic dysfunction
7) Patients with moderate or severe renal dysfunction (serum creatinine level should be 2 mg/dL or higher)
8) Patients with epilepsy or other convulsive disorders or a history of such disorders
9) Pregnant women, women who may be pregnant, and lactating women
10) Other patients deemed inappropriate by the attending physician
300
1st name | Satoshi |
Middle name | |
Last name | Takahashi |
Sapporo Medical University School of Medicine
Department of Infection Control & Laboratory Medicine
060-8543
S1 W16, Chuo-ku, Sapporo, Hokkaido
011-611-2111
stakahas@sapmed.ac.jp
1st name | Mitsuru |
Middle name | |
Last name | yasuda |
Sapporo Medical University School of Medicine
Department of Infection Control & Laboratory Medicine
060-8543
S1 W16, Chuo-ku, Sapporo, Hokkaido
011-611-2111
yasuda7jpe@sapmed.ac.jp
Sapporo Medical University School of Medicine
Sapporo Medical University School of Medicine
Other
Sapporo Medical University School of Medicine
S1 W17, Chuo-ku, Sapporo, Hokkaido
011-611-2111
ji-rskk@sapmed.ac.jp
NO
2022 | Year | 12 | Month | 26 | Day |
Unpublished
Enrolling by invitation
2022 | Year | 09 | Month | 22 | Day |
2022 | Year | 11 | Month | 10 | Day |
2023 | Year | 02 | Month | 01 | Day |
2025 | Year | 12 | Month | 31 | Day |
2022 | Year | 12 | Month | 26 | Day |
2023 | Year | 06 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056837
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |